Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
- Alterity Therapeutics Reports Progress and Financial Results
- Buy Rating for Alterity Therapeutics: Strong Financial Position and Promising Clinical Results
- Alterity Therapeutics Announces Change in Substantial Holding
- Alterity Therapeutics Expands Capital with New Securities Quotation
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue